Association of
FBN1 genetic variant(rs370096856) with serum Asprosin level among Type 2 Diabetes
Mellitus Subjects-A Cross Sectional Study
Mary Yanglem, Shetty Sukanya, Bhandary Roopa, Chakraborty Gunimala and Kulkarni
Vineet
Res. J. Biotech.; Vol. 20(8); 219-225;
doi: https://doi.org/10.25303/208rjbt2190225; (2025)
Abstract
The global burden of Type 2 diabetes mellitus (T2DM) continues to rise even with
advancement in therapeutic options. There is a pressing need for new biomarkers
to improve prognosis. Recent epidemiological and genetic studies have emphasized
the crucial role of serum asprosin levels in insulin resistance and diabetes complications.
However, the role of genetic variants in serum asprosin levels remains poorly understood.
Fifty subjects with T2DM who met the inclusion criteria were recruited for the study.
Serum asprosin levels were estimated using the ELISA method. SNP genotype analysis
for rs370096856 was conducted using PCR and Sanger sequencing.
The present study demonstrated that serum asprosin levels were significantly elevated
(p=0.012) in subjects with the GT genotype compared to those with GG and TT genotypes.
Among subjects with the GT genotype, asprosin levels showed a positive correlation
with TyG (r=0.6), LDL (r=0.78) and HbA1c (r=0.08). The ROC analysis revealed the
cut-off value of 2.9 ng/mL asprosin to predict the risk of T2DM.The present study
highlighted a positive correlation between asprosin and TyG among subjects with
GT genotype. Further multicentric studies with larger sample sizes are necessary
to confirm these findings.
